Hikari Power Ltd Sells 22,090 Shares of Amgen Inc. $AMGN

Hikari Power Ltd lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 71.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,900 shares of the medical research company’s stock after selling 22,090 shares during the period. Amgen makes up approximately 0.4% of Hikari Power Ltd’s holdings, making the stock its 19th largest holding. Hikari Power Ltd’s holdings in Amgen were worth $3,223,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Plato Investment Management Ltd boosted its holdings in Amgen by 2.7% during the 2nd quarter. Plato Investment Management Ltd now owns 22,412 shares of the medical research company’s stock valued at $8,068,000 after acquiring an additional 599 shares during the period. Hexagon Capital Partners LLC increased its stake in Amgen by 11.7% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,308 shares of the medical research company’s stock worth $474,000 after purchasing an additional 137 shares during the period. Roman Butler Fullerton & Co. increased its stake in Amgen by 1.4% in the 2nd quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock worth $705,000 after purchasing an additional 27 shares during the period. Simplicity Wealth LLC lifted its position in Amgen by 122.5% in the second quarter. Simplicity Wealth LLC now owns 10,539 shares of the medical research company’s stock valued at $3,816,000 after purchasing an additional 5,802 shares during the last quarter. Finally, Wealth Effects LLC lifted its position in Amgen by 5.6% in the second quarter. Wealth Effects LLC now owns 2,905 shares of the medical research company’s stock valued at $1,052,000 after purchasing an additional 155 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 6th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Argus dropped their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. Finally, Cantor Fitzgerald boosted their price objective on shares of Amgen from $350.00 to $400.00 and gave the company a “neutral” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $375.93.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent results reinforced its growth narrative: quarterly revenue rose 9.5% year over year to $10.05 billion, while adjusted earnings of $6.29 per share exceeded consensus by $0.67. Management’s fiscal 2026 EPS guidance of $22.30–$23.50 also supports the bullish outlook. Amgen Results Put Growth Back in Focus
• Positive Sentiment: A completed Phase 1 study comparing two evolocumab formulations provides continued support for Amgen’s cholesterol franchise. Evolocumab, marketed as Repatha, is an important commercial product, and formulation work could help support its future development and patient use. Amgen’s Evolocumab Formulation Study
• Positive Sentiment: Growth-focused analysis from Zacks highlights Amgen’s earnings profile and potential for continued performance, adding to the favorable investor narrative. Why Amgen Is a Strong Growth Stock
• Neutral Sentiment: Cantor Fitzgerald raised its Amgen price target to $400 but retained a Neutral rating. Mizuho also maintained Neutral while lifting its target to $352, indicating that analysts see some fundamental improvement but believe the recent rally has exceeded their valuation expectations.
• Negative Sentiment: Amgen exercised its right to terminate a partnership with TScan Therapeutics, removing a collaboration from TScan’s pipeline. While the direct financial effect on Amgen is unclear, the termination may raise questions about partnership prioritization or the development prospects of the related program. TScan Therapeutics Faces Loss of Key Amgen Partnership

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by insiders.

Amgen Stock Performance

NASDAQ:AMGN opened at $425.28 on Wednesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm’s fifty day simple moving average is $373.66 and its 200 day simple moving average is $360.06. The stock has a market cap of $229.92 billion, a P/E ratio of 26.43, a price-to-earnings-growth ratio of 3.86 and a beta of 0.41. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $427.39.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period in the prior year, the business earned $6.02 EPS. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts predict that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is presently 62.65%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.